Browse the evidence

VLCKD is contraindicated in patients with Type 1 Diabetes, renal failure, liver failure, and certain cardiac conditions due to risks of euglycemic ketoacidosis, electrolyte imbalance, and metabolic stress.

Do not attempt this diet if you have Type 1 Diabetes, kidney or liver disease, or severe heart failure. These conditions make the metabolic shift of ketosis dangerous. Consult your doctor for safer alternatives.

Lorcaserin was withdrawn from the US market in 2020 due to an increased risk of cancer observed in clinical trials, despite showing modest weight loss efficacy.

Lorcaserin (Belviq) is no longer available in the US because it was linked to a higher risk of cancer. Do not seek this medication.

Once-weekly mazdutide (3–6 mg) administered for 24 weeks produces robust, dose-dependent body weight reduction (up to 11.3%) and improves cardio-metabolic risk factors in Chinese overweight or obese adults.

For Chinese adults with obesity or overweight with related health issues, a once-weekly injection of mazdutide (up to 6 mg) for 24 weeks can lead to significant weight loss (up to 11%) and improved heart health markers. While gastrointestinal side effects like nausea are common, they are usually manageable and do not typically cause patients to stop treatment.

Once-weekly subcutaneous tirzepatide (5, 10, and 15 mg) produces significant, dose-dependent weight loss and improvements in cardiometabolic markers compared to placebo in adults with or without type 2 diabetes.

If you are an adult with obesity or overweight (with or without Type 2 Diabetes), once-weekly tirzepatide injections (5-15 mg) are a highly effective medical intervention for weight loss, averaging 8-12% body weight reduction depending on the dose. It also improves blood pressure, blood sugar, and lipids. While you may experience temporary gastrointestinal issues like nausea, these are usually mild and subside over time. This treatment is significantly more effective than older anti-obesity drugs and is generally safe, with no increased risk of serious adverse events compared to placebo.

Survodutide, a dual glucagon and GLP-1 receptor agonist, produces significant weight loss, BMI reduction, and waist circumference reduction in adults with overweight or obesity.

Survodutide is a once-weekly injection that significantly reduces weight, BMI, and waist size. The benefits are greater with higher doses (>2mg/week) and longer treatment durations (>16 weeks). It is particularly effective for individuals under 50 years old. Common side effects are gastrointestinal, but it offers a non-surgical option for weight management.

The efficacy of Survodutide for weight loss is conditional on dose and duration, with doses >2 mg/week and interventions >16 weeks yielding significantly greater reductions in weight and waist circumference.

To maximize weight loss with Survodutide, ensure you are on a dose above 2 mg/week and continue treatment for at least 16 weeks. Lower doses or shorter durations result in less significant weight and waist circumference reduction.

Weekly subcutaneous administration of Tirzepatide (5-15 mg) significantly reduces body weight and body fat percentage in non-diabetic obese patients compared to placebo, with effects comparable to bariatric surgery.

If you are obese and non-diabetic, Tirzepatide is a highly effective weekly injection that can lead to significant weight loss (up to ~21%) and fat loss, outperforming previous GLP-1 drugs. It requires a commitment to weekly injections and lifestyle changes (diet and 150 mins/week exercise), but may offer a better side-effect profile regarding nausea than older drugs due to its dual GIP/GLP-1 mechanism.

A once-weekly synthetic semaglutide formulation (test drug) provides weight loss efficacy and safety comparable to the innovator semaglutide (Wegovy) in Indian adults with obesity over a 24-week period.

If you are an adult in India with obesity who has struggled to lose weight through diet and exercise alone, this study shows that a once-weekly synthetic semaglutide injection works just as well as the brand-name version (Wegovy) over 24 weeks. You can expect to lose about 14-15% of your body weight if you follow the dose-titration schedule (starting low and increasing every 4 weeks) alongside a 500-calorie daily deficit and 150 minutes of weekly exercise. While you may experience common side effects like nausea or constipation, they are generally mild and manageable. This option may be more affordable than the brand name, making it a viable long-term management tool.

An 8-week Very Low Carbohydrate Diet (VLCD) in older adults with obesity promotes significantly greater loss of visceral adipose tissue (VAT) and intermuscular adipose tissue (IMAT) compared to a standard low-fat diet, while preserving skeletal muscle mass.

If you are an older adult with obesity, switching to a very low-carbohydrate diet (less than 10% of calories from carbs) for 8 weeks can help you lose visceral and intermuscular fat much faster than a standard low-fat diet, without losing your actual muscle mass. You don't need to count calories strictly; simply prioritizing fats and proteins while keeping carbs very low tends to naturally reduce calorie intake and improve insulin sensitivity.

A Very Low Carbohydrate Diet improves insulin sensitivity and favorable lipid profiles (increased HDL, decreased triglycerides) in older adults with obesity compared to a low-fat diet.

Beyond just weight loss, switching to a very low-carbohydrate diet can significantly improve your blood markers for heart health, specifically by lowering triglycerides and raising HDL cholesterol, more so than a standard low-fat diet would.

Tirzepatide (5 mg, 10 mg, and 15 mg) significantly reduces body weight in patients with type 2 diabetes and obesity compared to placebo, GLP-1 receptor agonists, and basal insulin.

Tirzepatide is a highly effective treatment for weight loss in people with T2DM or obesity, outperforming other common medications like GLP-1 agonists and insulin. It is taken as a once-weekly injection. While it causes gastrointestinal side effects like nausea and diarrhea, these are usually mild and temporary. If you are considering this, discuss the benefits of significant weight loss against the potential for temporary stomach issues with your doctor.

Subcutaneous Tirzepatide significantly reduces body weight, BMI, and waist circumference in adults with obesity or type 2 diabetes compared to placebo.

If you have obesity or type 2 diabetes and lifestyle changes haven't been enough, Tirzepatide is a highly effective, once-weekly injection that significantly reduces weight, BMI, and waist circumference. The effect is dose-dependent, with higher doses (up to 15mg) yielding greater weight loss. Be prepared for potential gastrointestinal side effects like nausea, which are common but often manageable.

In real-world clinical practice, tirzepatide produces significantly greater weight loss and higher rates of achieving clinically meaningful weight loss thresholds (≥5%, ≥10%, ≥15%) compared to semaglutide in adults with overweight or obesity.

If you are using tirzepatide (Mounjaro) or semaglutide (Ozempic) for weight loss, real-world data suggests that tirzepatide is more effective at helping you lose significant amounts of weight (10% or more of your body weight) compared to semaglutide. You are also more likely to reach these milestones faster with tirzepatide. However, both drugs carry similar risks of gastrointestinal side effects, so tolerability is a key factor in choosing between them.

Tirzepatide produces significantly greater weight loss than semaglutide in adults with obesity or overweight, with the magnitude of loss increasing with higher doses (>10 mg) and longer treatment durations (>6 months).

If you are using semaglutide and not achieving your weight loss goals, switching to tirzepatide (particularly at doses above 10 mg and continuing for more than 6 months) is likely to result in significantly greater weight loss. The data supports tirzepatide as a more potent option for reducing body weight compared to semaglutide.

Weekly administration of semaglutide at 2.4 mg induces significant weight loss (mean 14.9%) and improves glycemic control (HbA1c < 7.0% in 57-74% of patients) in adults with obesity or type 2 diabetes, with effects proportional to dose and duration.

If you have obesity or type 2 diabetes, weekly semaglutide (2.4 mg for weight loss, 1-1.0 mg for diabetes) is a highly effective treatment that can lead to significant weight loss (up to 15%) and better blood sugar control. While nausea and vomiting are common side effects, they are usually mild and temporary, and weight loss often occurs regardless of whether you experience them. An oral version is also available if you prefer to avoid injections. Discuss this with your doctor to see if it's right for you.

Tirzepatide produces significantly greater weight loss than semaglutide in overweight and obese adults, with a standardized mean difference of 0.75 favoring tirzepatide.

If you are choosing between tirzepatide and semaglutide for weight loss, current direct comparative evidence suggests tirzepatide may lead to greater weight reduction. This benefit comes with a dual-hormone mechanism (GIP/GLP-1) and requires weekly injections. You should expect potential gastrointestinal side effects during dose increases, which are usually manageable. Combining the medication with diet and exercise will likely enhance results.

Tirzepatide significantly increases the odds of achieving clinically meaningful weight loss (≥10% body weight reduction) compared to semaglutide.

A key benefit of tirzepatide over semaglutide is the increased likelihood of losing 10% or more of your body weight, a threshold often associated with significant health improvements. This makes tirzepatide a potentially more effective option if your primary goal is substantial weight reduction. Discuss with your provider whether this higher efficacy profile aligns with your health goals.

Oral semaglutide (50 mg once daily) is effective for weight loss in non-diabetic obese/overweight adults, though generally less effective than the subcutaneous 2.4 mg formulation.

If you prefer not to use injections, oral semaglutide (50 mg daily) is a viable option for weight loss in non-diabetic adults with obesity. It produces significant weight loss (average 15%), though it requires daily adherence. It is generally considered less effective than the weekly injectable form, so discuss with your provider which form best fits your lifestyle and medical needs.

Feeding during the biological rest phase (daytime for mice, nighttime for humans) disrupts circadian alignment and promotes obesity and metabolic disorders, whereas aligning food intake with the active phase restores metabolic rhythms and prevents weight gain.

Align your main meals with your active hours. If you work a standard day, avoid large meals late at night. If you are a shift worker, try to eat during your 'day' (active phase) and fast during your 'night' (rest phase), even if it is daylight outside. This synchronization helps your metabolic organs function efficiently.

Elderly individuals exhibit 'anabolic resistance,' requiring higher doses of protein (specifically ~20g whey or ~2.8g leucine) to stimulate muscle protein synthesis (MPS) above rest, compared to younger individuals who respond to lower doses (~5g protein).

If you are over 60, eating a standard serving of protein (e.g., 10g) likely won't build muscle. You need to consume about 20-25g of high-quality protein (like whey or eggs) per meal to trigger muscle growth. This is because aging muscles are 'resistant' and need a bigger signal (specifically ~2.8g of leucine) to start building muscle. Distribute this amount across 3-4 meals daily.

High consumption of sugar-sweetened beverages and high-glycemic load carbohydrates increases the risk of weight gain and type 2 diabetes, particularly in individuals with higher BMI or insulin resistance.

Limit sugar-sweetened beverages and foods with a high glycemic load, especially if you have a higher BMI or insulin resistance. Focus on whole grains and high-fiber carbohydrates instead, as these are associated with lower risks of weight gain and type 2 diabetes.

Subcutaneous semaglutide 2.4 mg once weekly produces 15–17% mean weight loss and offers cardioprotection in obesity treatment.

If you have obesity, subcutaneous semaglutide 2.4 mg once weekly is an approved treatment that can help you lose 15–17% of your body weight and may protect your heart. This is significantly more effective than lifestyle changes alone, which often fail to maintain weight loss long-term.

Tirzepatide, a dual GLP-1/GIP receptor agonist, achieves up to 22.5% mean weight loss in phase 3 obesity trials.

Tirzepatide is a dual-acting hormone medication (GLP-1/GIP) that can lead to up to 22.5% weight loss in clinical trials, surpassing single-agonist GLP-1 drugs. It is available for obesity management.

Oral semaglutide 50 mg once daily results in 17.4% weight loss in people with obesity without type 2 diabetes.

For those who prefer not to inject medication, oral semaglutide 50 mg once daily can achieve 17.4% weight loss in people with obesity without diabetes, comparable to the injectable version.